Jump to content
  • rosaceans.png.0fe8f26985ddf1de32765ef1ee

    We are rosaceans and this is a grassroots rosacea non profit organization. The entire board of directors are rosacea sufferers. Compare that with the other non profit rosacea organizations, run by NON rosaceans. We now allow guests to post here without registering an account.  

    We have an Invision Community public forum. A public forum allows the public to view the posts but only members can post (registering an account with your email is required). What is odd is that this format, while older than the social media platforms, i.e., Reddit, Facebook, Instagram, Twitter, etc., requires no more than what the social media platforms require, an email address. Maybe we lack a mobile app?  We are working on it with a beta version (read below). 


    You may enter the Public RRDi Invision Community Forum.

    There is a beta version mobile app for Android and for Apple devices with a beta iOS version available!


    Public Forum

    In a PUBLIC RRDi forum ALL posts are public and can be read whether you join or not. You may access the public forum url here: 


    We also have a Tapatalk Private Forum available (scroll below for more information). Private forums are just that, you cannot view the posts unless you join (the public can NOT view the posts)

    Tapatalk Enabled (private forum)



    Tapatalk App
    The RRDi member forum, a public group, used to be available using the Tapatalk app which you can download from the App Store or Google Playstore.  The Tapatalk app ONLY works for our private rosaceans forum. 

    Currently the Tapatalk app (Version 1.6.6 ) for our public forum using Invision Community Version 4.5.1 is not compatible so we have turned it OFF. We await whether Tapatalk will support the latest version of the Invision Community platform for our public forum. You can read more about the Tapatalk PRIVATE rosaceans forum below: 

    Private Tapatalk Rosaceans Group
    The RRDi is affiliated with Tapatalk and is sponsoring a PRIVATE Rosaceans  [rosaceans are rosacea sufferers] Tapatalk forum free for users which is a private group. If you are not familiar with the difference between a private member forum and a PUBLIC forum, the posts in a private forum are only read if you join. Here is the official announcement about our Rosaceans Tapatalk Private Forum which explains an option about Tapatalk Gold Points (not required but available for your consideration). You may access the private rosaceans group here:


    You are welcome to join either or both of our two member forums if you suffer from rosacea.  We will try the private Tapatalk forum for a year and if it is not popular we will probably drop it. So it is up to you whether having a private Rosaceans group is mo'betta than our Invision Community public forum which you can still use the Tapatalk application for our public Tapatalk member forum and our private group. The private Tapatalk is totally run on Tapatalk servers and has no issues using Tapatalk.  

  • Forum Statistics

    • Total Topics
    • Total Posts
  • Posts

    • "These findings demonstrate the broad‐spectrum antiviral property of ivermectin benefiting for COVID‐19 treatment in the context of predictive, preventive, and personalized medicine in virus‐related diseases." J Cell Physiol. 2020 Sep 22 : 10.1002/jcp.30055. doi: 10.1002/jcp.30055 [Epub ahead of print] Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment Na Li, Lingfeng Zhao,  Xianquan Zhan "Close to 70 clinical trials are currently in progress worldwide for SARS-CoV-2. Although few of these studies have been completed, the results that are available, as well as those from observational/retrospective studies, indicate clinical benefit. Here we discuss the case for ivermectin as a host-directed broad-spectrum antiviral agent, including for SARS-CoV-2." Biochem Biophys Res Commun. 2020 Oct 21 doi: 10.1016/j.bbrc.2020.10.042  The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2? David A. Jansa, Kylie M. Wagstaffb
    • Comments on "The Decrease of Demodex Density After Nd:YAG Laser Application for Facial Telengiactasias: A Case Report". Dermatol Ther. 2020 Oct 27;: Clatici VG, Voicu C, Barinova E, Tatu AL
    • Comments on "The Decrease of Demodex Density After Nd:YAG Laser Application for Facial Telengiactasias: A Case Report". Dermatol Ther. 2020 Oct 27;: Authors: Clatici VG, Voicu C, Barinova E, Tatu AL PMID: 33107672 [PubMed - as supplied by publisher] {url} = URL to article
    • The RRDi has been using Invision Community forum platform since 2004. When we started in 2004 it was recommended by Warren Stuart who was the assistant director of the RRDi to use what was then called Invision Power Services (later the name was changed to Invision Community). It is a powerful platform with many add-on features and a significant number of developers adding plugins and additional features to the platform. However, with the advent of mobile devices and social media platforms the trend has focused on mobile apps using iOS and Android devices found in the Apple App Store and Google Play Store. The popularity of using these apps over using a browser to view a website has increased the use of social media platforms such as Reddit, Facebook, Instagram, Twitter, etc. The developers and owners of the Invision Community platform have now announced beta versions of iOS and Android apps for their platform which has been embedded for years using only a web browser, so we have announced with this post here asking for volunteers to download the beta versions and help test these new apps. Please consider volunteering and using these beta versions of the apps.  Invision Community Clients There are some significant clients who use Invision Community as their platform which you can see below:  Medical Clients Who Use Invision Community Platform
    • Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide. Front Immunol. 2020;11:559589 Authors: Dondalska A, Rönnberg E, Ma H, Pålsson SA, Magnusdottir E, Gao T, Adam L, Lerner EA, Nilsson G, Lagerström M, Spetz AL Abstract Numerous inflammatory skin disorders display a high prevalence of itch. The Mas-related G protein coupled receptor X2 (MRGPRX2) has been shown to modulate itch by inducing non-IgE-mediated mast cell degranulation and the release of endogenous inducers of pruritus. Various substances collectively known as basic secretagogues, which include inflammatory peptides and certain drugs, can trigger MRGPRX2 and thereby induce pseudo-allergic reactions characterized by histamine and protease release as well as inflammation. Here, we investigated the capacity of an immunomodulatory single-stranded oligonucleotide (ssON) to modulate IgE-independent mast cell degranulation and, more specifically, its ability to inhibit the basic secretagogues compound 48/80 (C48/80)-and LL-37 in vitro and in vivo. We examined the effect of ssON on MRGPRX2 activation in vitro by measuring degranulation in a human mast cell line (LAD2) and calcium influx in MRGPRX2-transfected HEK293 cells. To determine the effect of ssON on itch, we performed behavioral studies in established mouse models and collected skin biopsies for histological analysis. Additionally, with the use of a rosacea mouse model and RT-qPCR, we investigated the effect on ssON on LL-37-induced inflammation. We reveal that both mast cell degranulation and calcium influx in MRGPRX2 transfected HEK293 cells, induced by the antimicrobial peptide LL-37 and the basic secretagogue C48/80, are effectively inhibited by ssON in a dose-dependent manner. Further, ssON demonstrates a capability to inhibit LL-37 and C48/80 activation in vivo in two mouse models. We show that intradermal injection of ssON in mice is able to block itch induced via C48/80 in a dose-dependent manner. Histological staining revealed that ssON inhibits acute mast cell degranulation in murine skin treated with C48/80. Lastly, we show that ssON treatment ameliorates LL-37-induced inflammation in a rosacea mouse model. Since there is a need for new therapeutics targeting non-IgE-mediated activation of mast cells, ssON could be used as a prospective drug candidate to resolve itch and inflammation in certain dermatoses. PMID: 33101278 [PubMed - in process] {url} = URL to article
  • Create New...